Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD)

NCT05683860 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
8
Enrollment
INDUSTRY
Sponsor class

Stopped Despite robust, sustained reductions in poly(GP), no clinical benefit was seen at 24 weeks, and reductions in poly(GP) were not associated with stabilization in functional outcomes. Based on these data, Wave decided to stop development of WVE-004.

Conditions

Interventions

Sponsor

Wave Life Sciences Ltd.